Advertisement

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opening Session Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




May
24
Today In Oncology
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo